Literature DB >> 17530996

Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTs.

Jay D Kissel1, Daniel M Held, Richard W Hardy, Donald H Burke.   

Abstract

Natural and selected resistance of HIV-1 to current anti-HIV drugs continues to pose serious problems to the development of HIV-1 antivirals. The viral reverse transcriptase (RT) is a proven therapeutic target. Single-stranded RNA and DNA (ssRNA and ssDNA) aptamers have been selected that specifically and potently inhibit RT function. In particular, the ssDNA aptamer RT1t49 was previously selected to recognize the RT from a subtype B strain of HIV-1 and binds with a reported K(d) of 4 nM. In the present work, we show that RT1t49 inhibits recombinant RT cloned from diverse branches of the primate lentiviral family. Aptamer concentrations required for half-maximal inhibition of all HIV-1, HIV-2, and SIV(CPZ) RTs assayed were in the low-to mid-nanomolar range for both polymerase and RNase H activities. Using pre-steady-state and order-of-addition kinetic analyses, we also established that this ssDNA aptamer competes with primer-template for access to RT, and that addition of a nucleoside analog RT inhibitor (NRTI) to the in vitro reaction enhanced the overall effectiveness of both drugs, while nonnucleoside analog RT inhibitors (NNRTIs) exhibited simple additivity. This is the first demonstration of universal inhibition of HIV and SIV(cpz) RTs by a nucleic acid aptamer and supports previous reports suggesting that resistance to RT1t49 may be exceptionally infrequent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530996     DOI: 10.1089/aid.2006.0262

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  25 in total

1.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

2.  Emerging Technologies for the Treatment of COVID-19.

Authors:  Hossein Aghamollaei; Rahim Sarvestani; Hamid Bakherad; Hamed Zare; Paul C Guest; Reza Ranjbar; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Authors:  Daniel M Held; Jay D Kissel; Sarah J Thacker; Daniel Michalowski; Dayal Saran; Jianfei Ji; Richard W Hardy; John J Rossi; Donald H Burke
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

4.  Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.

Authors:  Sergey Iordanskiy; Mackenzie Waltke; Yanjun Feng; Charles Wood
Journal:  Retrovirology       Date:  2010-10-12       Impact factor: 4.602

Review 5.  Functionalized gold nanoparticles: promising and efficient diagnostic and therapeutic tools for HIV/AIDS.

Authors:  Shikha Gulati; Parinita Singh; Anchita Diwan; Ayush Mongia; Sanjay Kumar
Journal:  RSC Med Chem       Date:  2020-10-01

6.  Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing.

Authors:  Margaret J Lange; Tarun K Sharma; Angela S Whatley; Linda A Landon; Michael A Tempesta; Marc C Johnson; Donald H Burke
Journal:  Mol Ther       Date:  2012-09-04       Impact factor: 11.454

7.  Novel bimodular DNA aptamers with guanosine quadruplexes inhibit phylogenetically diverse HIV-1 reverse transcriptases.

Authors:  Daniel Michalowski; Rebecca Chitima-Matsiga; Daniel M Held; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2008-11-07       Impact factor: 16.971

8.  Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells.

Authors:  Pantxika Bellecave; Christian Cazenave; Julie Rumi; Cathy Staedel; Ophélie Cosnefroy; Marie-Line Andreola; Michel Ventura; Laura Tarrago-Litvak; Thérèse Astier-Gin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

9.  High-throughput sequence analysis reveals structural diversity and improved potency among RNA inhibitors of HIV reverse transcriptase.

Authors:  Mark A Ditzler; Margaret J Lange; Debojit Bose; Christopher A Bottoms; Katherine F Virkler; Andrew W Sawyer; Angela S Whatley; William Spollen; Scott A Givan; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2012-12-14       Impact factor: 16.971

10.  Potent Inhibition of HIV-1 Reverse Transcriptase and Replication by Nonpseudoknot, "UCAA-motif" RNA Aptamers.

Authors:  Angela S Whatley; Mark A Ditzler; Margaret J Lange; Elisa Biondi; Andrew W Sawyer; Jonathan L Chang; Joshua D Franken; Donald H Burke
Journal:  Mol Ther Nucleic Acids       Date:  2013-02-05       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.